Greater cumulative exposure to ribavirin increases response to interferon–ribavirin combination therapy for hepatitis C but also induces more severe anaemia. Polymorphisms in the ITPA gene protect against ribavirin-induced anaemia. The maximum dosage of ribavirin that can be tolerated by patients with different ITPA polymorphisms remains unknown.
Methods
We developed a mathematical model of haemoglobin (Hb) decline in patients undergoing combination therapy. Using it to analyse published patient data, we estimated the average erythrocyte lifespan in patients with different ITPA polymorphisms. Coupled with a previous population pharmacokinetic study, we derived a formula for predicting the optimal ribavirin dosage, Dopt, above which anaemia becomes intolerable (Hb<10 g/dl).
Results
Our model provided good fits to patient data of ribavirin accumulation in erythrocytes and the ensuing Hb decline during therapy. With the current treatment protocol, the average erythrocyte lifespan was approximately 36 days in patients with wild-type ITPA activity, and approximately 43 days and 55 days, respectively, in patients with mild and moderate ITPA deficiency. Our model yielded a facile formula for estimating Dopt given a patient's weight, creatinine clearance, pretreatment Hb and ITPA polymorphism. Patients with moderate ITPA deficiency are predicted to tolerate twice the ribavirin dosage as patients with wild-type ITPA.
Conclusions
Our formula for Dopt presents an avenue for personalizing ribavirin dosage. By keeping anaemia tolerable, the predicted optimal dosage may improve adherence, reduce the need for drug monitoring, and increase response rates. Response rates may be increased further by the higher dosages recommended for patients with ITPA deficiency.
References
1.
LavanchyD.The global burden of hepatitis C. Liver Int2009; 29: 74–81.
2.
AwadT., ThorlundK., HauserG., StimacD., MabroukM., GluudC.Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology2010; 51: 1176–1184.
3.
KwongA.D., KauffmanR.S., HurterP., MuellerP.Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol2011; 29: 993–1003.
4.
PoordadF., McConeJ., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
5.
RongL., DahariH., RibeiroR.M., PerelsonA.S.Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med2010; 2: 30ra32.
6.
SulkowskiM.S.Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis2003; 37: S315–S322.
7.
ReddyK.R., ShiffmanM.L., MorganT.R.Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol2007; 5: 124–129.
8.
ReddyK.R., NelsonD.R., ZeuzemS.Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol2009; 50: 402–411.
9.
LindahlK., StahleL., BruchfeldA., SchvarczR.High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology2005; 41: 275–279.
10.
BodenheimerH.C., LindsayK.L., DavisG.L., LewisJ.H., ThungS.N., SeeffL.B.Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology1997; 26: 473–477.
11.
InoueY., HommaM., MatsuzakiY.Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res2006; 34: 23–27.
12.
De FranceschiL., FattovichG., TurriniF.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology2000; 31: 997–1004.
13.
VirtueM.A., FurneJ.K., HoS.B., LevittM.D.Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. Am J Hematol2004; 76: 107–113.
14.
KrishnanS.M., DixitN.M.Estimation of red blood cell lifespan from alveolar carbon monoxide measurements. Transl Res2009; 154: 15–17.
15.
SulkowskiM.S., WassermanR., BrooksL., BallL., GishR.Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat2004; 11: 243–250.
16.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
17.
ShiffmanM.L., SalvatoreJ., HubbardS.Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology2007; 46: 371–379.
18.
FalascaK., UcciferriC., MancinoP., GorgorettiV., PizzigalloE., VecchietJ.Use of epoetin beta during combination therapy of infection with hepatitis C virus with ribavirin improves a sustained viral response. J Med Virol2010; 82: 49–56.
19.
FellayJ., ThompsonA.J., GeD.ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature2010; 464: 405–408.
20.
ThompsonA.J., FellayJ., PatelK.Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology2010; 139: 1181–1189.
21.
OchiH., MaekawaT., AbeH.ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy: a genome-wide study of Japanese HCV virus patients. Gastroenterology2010; 139: 1190–1197.
22.
ThompsonA.J., SantoroR., PiazzollaV.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology2011; 53: 389–395.
23.
BruchfeldA., LindahlK., SchvarczR., StahleL.Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit2002; 24: 701–708.
24.
SpivakJ.L.The blood in systemic disorders. Lancet2000; 355: 1707–1712.
25.
KrishnanS.M., DixitN.M.Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLOS Comput Biol2011; 7: e1001072.
26.
GlueP.The clinical pharmacology of ribavirin. Semin Liver Dis1999; 19: 17–24.
27.
JarvisS.M.Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol1998; 123: 1587–1592.
28.
EndresC.J., MossA.M., KeB.The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther2009; 329: 387–398.
29.
PawlotskyJ.M., DahariH., NeumannA.U.Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology2004; 126: 703–714.
30.
DixitN.M., Layden-AlmerJ.E., LaydenT.J., PerelsonA.S.Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature2004; 432: 922–924.
31.
BerkP.D., BerlinN.I., BlaschkeT.F., BloomerJ.R., HoweR.B.Bilirubin production as a measure of red-cell life-span. J Lab Clin Med1972; 79: 364–378.
32.
MahaffyJ.M., BelairJ., MackeyM.C.Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis. J Theor Biol1998; 190: 135–146.
33.
BeckW.S.Hematology. Cambridge, Massachusetts: MIT Press1991.
34.
HitomiY., CirulliE.T., FellayJ.Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology2011; 140: 1314–1321.
35.
GhanyM.G., NelsonD.R., StraderD.B., ThomasD.L., SeeffL.B.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology2011; 54: 1433–1444.
36.
SheridanC.New Merck and Vertex drugs raise standard of care in hepatitis C. Nat Biotechnol2011; 29: 553–554.
37.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
38.
LandaverdeC., SaabS.Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations. Curr Hepat Rep2009; 8: 43–51.
39.
MorelloJ., Rodriguez-NovoaS., Jimenez-NacherI., SorianoV.Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother2008; 62: 1174–1180.
40.
BrochotE., CastelainS., DuverlieG., CapronD., Nguyen-KhacE., FrançoisC.Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther2010; 15: 687–695.
41.
TodM., Farcy-AffM., StoccoJ.Pharmacokinetic/ pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet2005; 44: 417–428.
42.
DebRoyS., Kribs-ZaletaC., MubayiA.Evaluating treatment of hepatitis C for hemolytic anemia management. Math Biosci2010; 225: 141–155.
43.
Loustaud-RattiV., AlainS., RousseauA.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology2008; 47: 1453–1461.
44.
ChayamaK., HayesC.N., AbeH.IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis2011; 204: 84–93.
45.
SuzukiF., SuzukiY., AkutaN.Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology2011; 53: 415–421.
46.
BirerdincA., EstepM., AfendyA.Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). J Viral Hepat2012; 19: 414–422.
47.
DixitN.M., PerelsonA.S.The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci2006; 63: 832–842.
48.
PrestonS.L., DrusanoG.L., GlueP., NashJ., GuptaS.K., McNamaraP.Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother1999; 43: 2451–2456.
49.
YuM-L, ChuangW-L. Treatment of chronic hepatitis C in Asia: when east meets west. J Gastroenterol Hepatol2009; 24: 336–345.
